Navigation Links
Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
Date:9/11/2008

MONTVALE, N.J., Sept. 11 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced findings from a study that indicated Synvista's proprietary monoclonal enzyme immunoassay can determine a person's haptoglobin pheno/genotype in less than two hours, and can aid physicians in predicting cardiovascular risk in patients with diabetes. The study was presented today at the 2008 Cardiovascular Biomarkers and Surrogate Endpoints Symposium in Bethesda, Maryland.

"This study shows the utility of our proprietary technology to diagnose Hp2-2 Diabetes, a disease affecting almost 7 million people in the United States," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics. "We believe that the ease of use of our haptoglobin diagnostic technology and rapid results bode well for its acceptance as an important tool in the treatment of cardiovascular disease in diabetic patients. In addition, we believe that the development of genetic markers like those identified by our test will continue to pave the way toward a personalized medicine model that will benefit a wider variety of patients in a more direct and reliably predictive manner."

In the study, investigators developed an ELISA (enzyme-linked immunosorbent assay) using a monoclonal antibody that differentiates between the three haptoglobin pheno/genotypes. Blood samples from diabetic patients with known haptoglobin pheno/genotypes were tested using Synvista's proprietary methodology. Results demonstrated 99.5% accuracy in determining each of the three haptoglobin types (48/48 Hp 1-1, 49/49 Hp2-1 and 90/91 Hp-2-2) with a greater than or equal to 98% sensitivity and specificity for each phenotype.

Additionally, a second paper was presented at the Symposium highlighting the use of Synvista's proprietary diagnostic kit for quantifying carboxymethyl-lysine (CML), a dominant advanced glycation end product (A.G.E.). The study demonstrated that CML is a biomarker of mortality in the elderly.

About Haptoglobin

The best understood function of haptoglobin (Hp), a common serum protein, is to bind free hemoglobin released from red blood cells. Extracellular hemoglobin (hemoglobin not found in red blood cells) is a potent oxidizing agent capable of inflicting oxidative tissue damage. Haptoglobin binds to this extracellular hemoglobin and inhibits hemoglobin induced oxidation. Once hemoglobin is bound to haptoglobin, it is rapidly cleared from the bloodstream by the liver or specialized white blood cells.

Haptoglobin in humans exists as three different proteins that arise from one of three haptoglobin gene combinations in the population, Hp 1-1 (16%), Hp2-2 (36%) and Hp1-2 (48%) For a variety of reasons, well described in the literature, Hp2-2 is more effective than Hp1-1 at preventing hemoglobin-induced oxidation in the bloodstream and blood vessel wall.

As a result, scientists have determined that the rate of heart disease is five times higher in Hp2-2 Diabetes than in Hp1-1 Diabetes. Hp2-2 Diabetes also has higher rates of myocardial infarction and re-vascularization within one year of angioplasty, and of heart failure and death following a heart attack. Prospective clinical trials have demonstrated that the rate of heart attack in Hp2-2 Diabetes can be decreased by the administration of natural Vitamin E (400IU). This combination of testing and treatment exemplifies pharmacogenomics, the targeting of a particular drug on the basis of genetic testing.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure. Diastolic heart failure represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database.

For more information, please visit the Company's Web site at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
2. Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
3. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
4. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
5. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
6. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
7. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
8. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
9. Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
10. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
11. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Diversified Holdings (NYSE: CODI ) ("CODI," "we," ... market businesses, announced today its consolidated operating results for ... First Quarter 2016 Highlights , Generated Cash Flow ... of $13.6 million for the first quarter of 2016; ... the first quarter of 2016; , Paid a ...
(Date:5/4/2016)... YORK , May 4, 2016 ... Share, Development, Growth and Demand Forecast to 2022 - Industry ... User (Hospital, Diagnostic Center and Others)" by P&S Market Research, ... $4,894.3 million in 2015, and it is expected to grow ... type, the high slice type segment is expected to witness ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Multiple Myeloma Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Multiple Myeloma market valuations and forecast, ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... A local study examining asthma ... 40 percent of participating fifth-grade students already have or are at risk for ... Research in the Division of Pulmonary, Allergy and Critical Care Medicine at ...
(Date:5/5/2016)... ... May 05, 2016 , ... Sun Health registered ... the organization’s successful Care Transitions program at the 9th Annual Orthopedic ... “Minimizing Costs in the Post-Acute Environment Through Effective Transitions of Care.” , Major ...
(Date:5/5/2016)... ... May 05, 2016 , ... Talent Tech Labs (TTL) is pleased ... of National Nurses Week (May 6-12). Currently, HireNurses is a job listing ... into the Talent Tech Lab Virtual Incubation program, they will dramatically expand the functionality ...
(Date:5/5/2016)... ... , ... The Lung Institute will celebrate its three-year anniversary on May 14 by ... throughout the month of May. To date, the Lung Institute has treated over 2,000 people ... is a testament to the success of this treatment and to the patients who refuse ...
(Date:5/5/2016)... ... ... summer is just around the corner. Summer means a lot of different things to people. ... play all day and night. Parents often lament the coming of summer as they will ... means trips to the beach, backyard cookouts, fireworks on the Fourth of July, and even ...
Breaking Medicine News(10 mins):